Introduction to Single-Cell Physiologically-Based Pharmacokinetic (scPBPK) Models.
A, S. & JM, G. (2026). Introduction to Single-Cell Physiologically-Based Pharmacokinetic (scPBPK) Models.. CPT: pharmacometrics & systems pharmacology. https://doi.org/10.1002/psp4.70320
A S, JM G. Introduction to Single-Cell Physiologically-Based Pharmacokinetic (scPBPK) Models.. CPT: pharmacometrics & systems pharmacology. 2026; doi: 10.1002/psp4.70320
A S, JM G. Introduction to Single-Cell Physiologically-Based Pharmacokinetic (scPBPK) Models.[J]. CPT: pharmacometrics & systems pharmacology. 2026. DOI: 10.1002/psp4.70320.
@article{a2026,
author = {Saini A and Gallo JM},
title = {Introduction to Single-Cell Physiologically-Based Pharmacokinetic (scPBPK) Models.},
journal = {CPT: pharmacometrics & systems pharmacology},
year = {2026},
doi = {10.1002/psp4.70320},
note = {PMID: 42625210},
}
TY - JOUR AU - Saini A AU - Gallo JM TI - Introduction to Single-Cell Physiologically-Based Pharmacokinetic (scPBPK) Models. T2 - CPT: pharmacometrics & systems pharmacology PY - 2026 DO - 10.1002/psp4.70320 AN - PMID:42625210 ER -
The current investigation introduces single-cell physiologically based pharmacokinetic (scPBPK) models to gain insight into drug disposition at the cellular scale. The transition from standard PBPK (sPBPK) models to scPBPK models required depiction of expression-dependent (ED) processes, such as drug metabolism or membrane transport. ED processes utilize weighting functions-a defined or data-driven distribution-that yield heterogeneity in individual cell kinetics. Two scPBPK model examples are provided, one involving a drug (AZD1775) subject to three ED blood-brain barrier transport processes, and another drug (midazolam) with a single ED process of metabolism by hepatocytes. For both examples, the weighting function for each ED process was defined by a negative binomial distribution that is often used in scRNAseq analytics. The AZD1775 model simulations indicated a large degree of single-cell drug concentration heterogeneity, whereas those for midazolam did not due to high membrane transport relative to metabolism. scPBPK models offer a means to probe cellular pharmacokinetics compatible with modern omic technologies and may be extended to pharmacodynamic models.